Cidara Therapeutics (CDTX) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 4:37 PM EDTSAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its corporate activities and product pipeline.
The recently received $20.0Â million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYOTM (rezafungin for injection) further strengthened our balance sheet, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.... More
